Determination of Rate and Extent of Scopolamine Release from Transderm Scōp® Transdermal Drug Delivery Systems in Healthy Human Adults

Suresh Kumar Swaminathan, Caroline Strasinger, Megan Kelchen, Jamie Carr, Wei Ye, Anna Wokovich, Priyanka Ghosh, Srinivasan Rajagopal, Kenichi Ueda, James Fisher, Karunya K. Kandimalla, Nicole K. Brogden

Research output: Contribution to journalArticle

Abstract

To estimate strength of a scopolamine transdermal delivery system (TDS) in vivo, using residual drug vs. pharmacokinetic analyses with the goal of scientifically supporting a single and robust method for use across the dosage form and ultimately facilitate the development of more consistent and clinically meaningful labeling. A two-arm, open-label, crossover pharmacokinetic study was completed in 26 volunteers. Serum samples were collected and residual scopolamine was extracted from worn TDS. Delivery extent and rate were estimated by (1) numeric deconvolution and (2) steady-state serum concentration determined from graphical and non-compartmental analyses. In residual drug analyses, mean ± SD scopolamine release rate was 0.015 ± 0.002 mg/h (11% RSD), vs. 0.016 ± 0.006 mg/h (35% RSD) from numeric deconvolution, 0.015 ± 0.005 mg/h (34% RSD) from graphical analysis, and 0.015 ± 0.007 mg/h (44% RSD) from non-compartmental analysis. In residual drug analyses, total drug released was 1.09 ± 0.11 mg (10% RSD), vs. 1.12 ± 0.40 mg (35% RSD) from numeric deconvolution, 1.07 ± 0.35 mg (33% RSD) from graphical analysis, and 1.07 ± 0.45 (42% RSD) from non-compartmental analysis. Extent and rate of scopolamine release were comparable by both approaches, but pharmacokinetic analysis demonstrated greater inter-subject variability.

Original languageEnglish (US)
Article number117
JournalAAPS PharmSciTech
Volume21
Issue number3
DOIs
StatePublished - Apr 1 2020

Keywords

  • pharmacokinetics
  • scopolamine
  • transdermal

Fingerprint Dive into the research topics of 'Determination of Rate and Extent of Scopolamine Release from Transderm Scōp® Transdermal Drug Delivery Systems in Healthy Human Adults'. Together they form a unique fingerprint.

  • Cite this

    Swaminathan, S. K., Strasinger, C., Kelchen, M., Carr, J., Ye, W., Wokovich, A., Ghosh, P., Rajagopal, S., Ueda, K., Fisher, J., Kandimalla, K. K., & Brogden, N. K. (2020). Determination of Rate and Extent of Scopolamine Release from Transderm Scōp® Transdermal Drug Delivery Systems in Healthy Human Adults. AAPS PharmSciTech, 21(3), [117]. https://doi.org/10.1208/s12249-020-01658-4